MedTrace Logo

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

NCT04569032 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2026-02-18

Study results available
· View outcomes & findings →

Summary

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.

Conditions

  • Peripheral T-cell Lymphoma

Interventions

DRUG

brentuximab vedotin

1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

DRUG

cyclophosphamide

750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

DRUG

doxorubicin

50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle

DRUG

prednisone

100 mg daily administered orally on Days 1-5 of each cycle

Sponsors & Collaborators

  • Seagen, a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-12
Primary Completion
2024-05-09
Completion
2026-01-12
FDA Drug
Yes

Countries

  • United States
  • France
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04569032 on ClinicalTrials.gov